The device is a variant of Neuralink's brain implant technology, in this case designed to "enable even those who have lost both eyes" to see, according to owner Elon Musk. Separately, progress is ...

Vanda Pharmaceuticals (VNDA) stock saw a 9% premarket drop after FDA rejection of its therapy for gastroparesis, citing need ...

Natural supplements have “very mild effects” on weight loss based on what Dr. Ali has seen. There is some data to suggest ...

Eli Lilly stock may look expensive, but that may not be the case in a few years as the business grows at a rapid pace.

Eli Lilly, a prominent player in the,Healthcare sector,, has experienced a significant rise in its stock price, driven by the ...

This is thanks to Lilly's dominance in the billion-dollar weight loss drug market. Lilly's Mounjaro and Zepbound have helped ...

Bioage's experimental drug, azelaprag, being developed to treat obesity, is a GLP-1 agonist, just as Eli Lilly's Zepbound and Novo Nordisk's Wegovy. Some analysts estimate that the market for these ...

In the obesity drug industry, two players have really been throwing their weight around. There isn’t a third in sight.

The S&P 500 ended 0.3% lower on Wednesday, Sept. 18, 2024, as the Federal Reserve announced its first interest-rate cut since ...

There is soaring demand for weight-loss drugs in the GLP-1 class, and the company will now sell it to certain professions for ...